

**Table 1s. Clinical and demographic characteristics of our multicenter cohort of SSc-ILD patients comparing patients with and without 12 months follow-up data.**

| Clinical and demographic characteristics | Follow-up<br>(40 patients) | No Follow-up<br>(50 patients) | p-value      |
|--|----------------------------|-------------------------------|--------------|
| Females, n (%)                           | 25 (62.5)                  | 40 (80)                       | 0.097        |
| Age (years), mean $\pm$ SD               | 58.6 $\pm$ 13.0            | 56.8 $\pm$ 13.8               | 0.539        |
| Disease duration (years), mean $\pm$ SD  | 8.7 $\pm$ 7.7              | 8.7 $\pm$ 7.8                 | 0.999        |
| Smokers, n (%) (active or former)        | 9 (22.5)                   | 9 (18)                        | 0.566        |
| <i>Cutaneous subset</i>                  |                            |                               |              |
| Diffuse, n (%)                           | 14 (45.0)                  | 16 (32)                       | 0.368        |
| Limited, n (%)                           | 16 (40)                    | 25 (50)                       | 0.288        |
| Sine scleroderma, n (%)                  | 1 (2.5)                    | 8 (16)                        | <b>0.040</b> |
| <i>Autoantibodies</i>                    |                            |                               |              |
| Anti-topoisomerase I Ab, n (%)           | 30 (75)                    | 37 (74)                       | 0.999        |
| Anti-RNA-polymerase III Ab, n (%)        | 2 (5)                      | 0 (0)                         | 0.195        |
| Anti-centromere Ab, n (%)                | 2 (5)                      | 3 (6)                         | 0.999        |
| <i>Organ involvement</i>                 |                            |                               |              |
| GI involvement                           | 36 (90)                    | 47 (94)                       | 0.789        |
| Myositis                                 | 4 (10)                     | 5 (10)                        | 0.999        |
| Myocarditis                              | 7 (17.5)                   | 3 (6)                         | 0.102        |
| Scleroderma Renal Crisis                 | 0 (0)                      | 0 (0)                         | 0.999        |
| Digital Ulcer                            | 5 (12.5)                   | 6 (12)                        | 0.935        |
| Pulmonary Arterial Hypertension          | 1 (1)                      | 0 (0)                         | 0.495        |
| <i>Baseline HRCT</i>                     |                            |                               |              |
| NSIP, n (%)                              | 25 (62.5)                  | 36 (73)                       | 0.359        |
| UIP, n (%)                               | 15 (37.5)                  | 13 (26.5)                     | 0.268        |
| <i>Baseline PFTs</i>                     |                            |                               |              |
| %pFVC                                    | 64.3 $\pm$ 18              | 64.1 $\pm$ 19                 | 0.899        |
| %pTLC                                    | 65.2 $\pm$ 17              | 64.5 $\pm$ 18                 | 0.855        |
| %pDLCO                                   | 37.3 $\pm$ 16              | 40.7 $\pm$ 18                 | 0.668        |

N= number; SD= standard deviation; Ab= antibodies; GI= gastro-intestinal; NSIP= non-specific interstitial pneumonia; UIP= usual interstitial pneumonia.